Clinical trials: Breast Neoplasms, Triple-Negative
Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer
Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
This is a first-in-human, multicenter, open-label Phase I/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral Zn-Telomir monotherapy in adults with advanced…
- Conditions
- Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer, Metastatic Triple-negative Breast Cancer
- Trial name
- NCT07581314
- Testing
- Zn-Telomir
- Volunteers
- 76 people
- Sponsor
- Telomir Pharmaceuticals, Inc.
Triple-negative Breast Cancer
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Triple negative breast cancer (TNBC), characterized by estrogen receptor, progesterone receptor and HER2 negative, accounts for 10-20% of all breast cancers and usually occurs in young women.
- Trial name
- NCT04213898
- Testing
- SHR-1210+Albumin-bound paclitaxel + epirubicin
- Volunteers
- 39 people
- Sponsor
- Henan Cancer Hospital
Advanced Metastatic Triple-negative Breast Cancer (mTNBC)
A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and…
- Trial name
- NCT07340424
- Testing
- 225Ac-TR2205 Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Xiaorong Sun
Solid Tumor Cancer, Solid Tumor, Unspecified, Adult
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
- Conditions
- Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC)
- Trial name
- DESCENT-1 (NCT06885424)
- Testing
- No additional intervention administered in this long term follow-up study
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- A2 Biotherapeutics Inc.
Advanced Solid Tumor, Advanced Cancer
NBE-002 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04441099
- Testing
- NBE-002
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- NBE-Therapeutics AG
Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic
First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
The goal of this clinical trial is to learn if the drug Sacituzumab govitecan (SG) reduces disease progression when used as a first-line treatment in adults with advanced triple-negative breast cancer (TNBC) who have not received…
- Conditions
- Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast Cancer
- Trial name
- NCT07299409
- Testing
- Sacituzumab Govitecan (SG)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Nathalie Levasseur
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: Cohort A: CRC Cohort B: Gastric…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
- Trial name
- NCT05453825
- Testing
- navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy
- Where
- 8 sites in United States
- Volunteers
- 180 people
- Sponsor
- OncXerna Theraputics, Inc.
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
IACS-010759 in Advanced Cancers
This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 (IACS-010759) in treating patients with lymphoma that has come back (relapsed) or does not respond to treatment…
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT03291938
- Testing
- Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacodynamic Study, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00834678
- Testing
- bendamustine, erlotinib, Maintenance erlotinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is most effective in treating breast cancer.
- Trial name
- NCT00640861
- Testing
- CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Breast Cancer
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
The purpose of this trial is to evaluate 2-year disease-free survival in this patient population treated with single agent cisplatin and patients treated with cisplatin in combination with Rucaparib following preoperative…
- Trial name
- NCT01074970
- Testing
- Cisplatin, Rucaparib
- Where
- 27 sites in United States
- Volunteers
- 135 people
- Sponsor
- Hoosier Cancer Research Network
Triple Negative Breast Cancer
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) worldwide. The term triple negative means that tumor growth is not stimulated by the hormones estrogen and progesterone, nor by the HER2…
- Trial name
- TRIFOUR (NCT05181462)
- Testing
- Carboplatin, Gemcitabine, Nadunolimab
- Where
- 23 sites in Spain
- Volunteers
- 117 people
- Sponsor
- Cantargia AB
Neoplasms
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.
- Trial name
- ARCS-Multi (NCT03102320)
- Testing
- Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Bayer
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO) plus electroporation (EP) in combination with pembrolizumab therapy.
- Trial name
- NCT03567720
- Testing
- tavokinogene telseplasmid, Pembrolizumab, Immunopulse
- Where
- 14 sites in United States, Australia
- Volunteers
- 65 people
- Sponsor
- OncoSec Medical Incorporated
Breast Cancer
Triple Negative Breast Cancer: Study of Molecular and Genetic Factors
Breast cancer triples negatives (TN; 15 % of the cases) are characterized by a high histoprognostic grade, a strong proliferation, a strong metastatic power, and a worse prognosis than the other forms of breast cancer.
- Trial name
- NCT01434420
- Testing
- BRCA1 BRCA2 PTEN PALB2 mutation
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Triple Negative Breast Cancer
Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients
The PERCEPTION study aims to assess the correlation between blood cell counts (Leucocytes, Neutrophils, Lymphocytes, Platelets, NLR (Neutrophil-to-Lymphocyte Ratio) and PLR (Platelet-to-Lymphocyte Ratio)) and Tumor Infiltrating…
- Trial name
- PERCEPTION (NCT04068623)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Centre Jean Perrin
Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma
- Trial name
- NCT02365662
- Testing
- ABBV-221
- Where
- 5 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- AbbVie
Triple Negative Breast Cancer
Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC
Trilaciclib is a highly potent, selective, and reversible CDK4/6 inhibitor that protects bone marrow by protecting hematopoietic stem cells and progenitor cells (HSPCs) during systemic chemotherapy.
- Trial name
- NCT06955156
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- QIAO LI
Triple-Negative Breast Neoplasm
Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC
A single-arm, single-institution study to induce phenotypic changes in the tumor microenvironment by delivering 8Gy partial breast irradiation in immune-cold triple-negative breast cancer confirmed by PD-L1 and TILs.
- Trial name
- KEY-MELT (NCT07011823)
- Testing
- Partial breast-irradiation
- Volunteers
- 20 people
- Sponsor
- Gangnam Severance Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.